Osiris has successful pre-BLA meeting for stem cell therapy
This article was originally published in Scrip
Executive Summary
Osiris Therapeuticshas held a successful pre-BLA meeting with the US FDA for its stem cell therapy, Prochymal, for the treatment of graft-versus-host disease (GvHD) in which the content and timings of the BLA submission was finalised.